Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL
Work
Year: 2020
Type: article
Abstract: The anti-CD19 chimeric antigen receptor (CAR)–T cell therapy tisagenlecleucel was evaluated in the global, phase 2 JULIET study in adult patients with relapsed/refractory diffuse large B-cell lymphom... more
Source: Blood Advances
Institutions Peter MacCallum Cancer Centre, The University of Melbourne, Medical University of Vienna, University Hospital Cologne, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute +16 more
Cites: 27
Cited by: 120
Related to: 10
FWCI: 8.859
Citation percentile (by year/subfield): 100
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: gold
APC paid (est): $3,000